| FCHL | familial combined hyperlipidemia |
|---|---|
| NS | 1) Nephrotic Syndrome 1. Proteinuria &nb... |
| EHL | effective half-life; electrohydraulic lipotripsy; endogenous hyperlipidemia; Environmental Health La... |
| HL | hairline; hairy leukoplakia; half life; hearing level; hearing loss; heparin lock; histiocytic lymph... |
| PS test | Pancreozymin-Secretion test = combined secretin-CCK test |
| CHL | Combined hyperlipidemia |
|---|---|
| FCHL | Familial Combined Hyperlipidemia |
| HL | Hyperlipidemia |
| CSE | Combined Spinal-Epidural |
| CAB | Combined androgen blockade |
| hyperlipidemia, familial combined | A disorder genetically distinct from the other inherited hyperlipidemias characterised by the type II or type IV lipoprotein pattern (the pattern may change from time to time and the lipid level may be normal at one time and abnormal at another time). (12 Dec 1998) |
|---|---|
| mixed hyperlipidemia | mixed hyperlipoproteinaemia familial, type 5 hyperlipidemia |
| hyperlipidemia | <biochemistry> A general term for elevated concentrations of any or all of the lipids in the plasma, such as cholesterol, triglycerides and lipoproteins. Origin: Gr. Haima = blood (18 Nov 1997) |
| anaesthetics, combined | The use of two or more chemicals simultaneously or sequentially to induce anaesthesia. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antibiotics, combined | Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antineoplastic agent, combined | The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. (12 Dec 1998) |
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| combined cycle | Two or more generation processes in series or in parallel, configured to optimise the energy output of the system. (05 Dec 1998) |
| combined-cycle power plant | The combination of a gas turbine and a steam turbine in an electric generation plant. The waste heat from the gas turbine provides the heat energy for the steam turbine. (05 Dec 1998) |
| combined fat-and carbohydrate-induced hyperlipaemia | Hyperlipoproteinaemia characterised by increased plasma levels of chylomicrons, VLDL, pre-beta-lipoproteins, and triglycerides, and slight rise of cholesterol on a normal diet, with beta-lipoproteins normal; may be accompanied by bouts of abdominal pain, hepatosplenomegaly, susceptibility to atherosclerosis, and abnormal glucose tolerance; probably autosomal recessive inheritance. Synonym: combined fat-and carbohydrate-induced hyperlipaemia, familial hyperchylomicronaemia with hyperprebetalipoproteinaemia, mixed hyperlipaemia. (05 Mar 2000) |
| combined glaucoma | Glaucoma with angle-closure and open-angle mechanisms in the same eye. (05 Mar 2000) |
| combined heat and power | An older term for what is now generally called cogeneration. The term is currently used in Europe and other foreign countries. (05 Dec 1998) |
| combined immunodeficiency | <immunology> Congenital immunodeficiency with thymic agenesis, lymphocyte depletion and hypogammaglobulinaemia: both cellular and humoral immune systems are affected and life expectancy is low unless marrow transplantation is successful. (18 Nov 1997) |
| combined immunodeficiency syndrome | <syndrome> A serious primary immunodeficiency affecting both T and B-cells. (05 Mar 2000) |
| combined modality therapy | <oncology> Two or more types of treatments used to supplement each other. For instance, surgery, radiation, chemotherapy, hormonal or immunotherapy may be used alternatively or together for maximum effectiveness. (09 Oct 1997) |
| combined hyperlipidemia |
The concomitant elevation of total triglyceride level above 200 mg per dL and LDL-C level above 100, 130, or 160 mg per dL, depending on National Cholesterol Education Program risk factors.
출처: www.lipoprofile.com/control.cfm
|
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|